OBJECTIVES: Despite recommendations for vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) for all adults at increased risk of infection, several US states have reported increases in HAV and HBV infections among persons who inject drugs. We investigated hepatitis A and hepatitis B vaccination coverage among a sample of persons who reported injecting drugs and had evidence of hepatitis C virus (HCV) infection. METHODS: We searched the Wisconsin Immunization Registry for the vaccination records of persons who underwent HCV testing at syringe services programs from January 1 through August 31, 2018, and were reported to the Wisconsin Division of Public Health as having positive HCV antibody test results and a history of injection drug use. We calculated the percentage of persons who were vaccinated according to national recommendations. RESULTS: Of 215 persons reported, 204 (94.9%) had a client record in the Wisconsin Immunization Registry. Of these 204 persons, 66 (32.4%) had received ≥1 dose of hepatitis A vaccine, 46 (22.5%) had received 2 doses of hepatitis A vaccine, and 115 (56.4%) had received 3 doses of hepatitis B vaccine. Hepatitis B vaccine coverage decreased with increasing age, from 88.0% (22 of 25) among adults aged 20-24 to 30.3% (10 of 33) among adults aged 35-39. CONCLUSIONS: These findings suggest that most persons who inject drugs in Wisconsin are susceptible to HAV infection and that most persons aged ≥35 who inject drugs are susceptible to HBV infection. In addition to routine vaccination of children, targeted hepatitis vaccination programs should focus on adults who inject drugs to help prevent future infections.
OBJECTIVES: Despite recommendations for vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) for all adults at increased risk of infection, several US states have reported increases in HAV and HBV infections among persons who inject drugs. We investigated hepatitis A and hepatitis B vaccination coverage among a sample of persons who reported injecting drugs and had evidence of hepatitis C virus (HCV) infection. METHODS: We searched the Wisconsin Immunization Registry for the vaccination records of persons who underwent HCV testing at syringe services programs from January 1 through August 31, 2018, and were reported to the Wisconsin Division of Public Health as having positive HCV antibody test results and a history of injection drug use. We calculated the percentage of persons who were vaccinated according to national recommendations. RESULTS: Of 215 persons reported, 204 (94.9%) had a client record in the Wisconsin Immunization Registry. Of these 204 persons, 66 (32.4%) had received ≥1 dose of hepatitis A vaccine, 46 (22.5%) had received 2 doses of hepatitis A vaccine, and 115 (56.4%) had received 3 doses of hepatitis B vaccine. Hepatitis B vaccine coverage decreased with increasing age, from 88.0% (22 of 25) among adults aged 20-24 to 30.3% (10 of 33) among adults aged 35-39. CONCLUSIONS: These findings suggest that most persons who inject drugs in Wisconsin are susceptible to HAV infection and that most persons aged ≥35 who inject drugs are susceptible to HBV infection. In addition to routine vaccination of children, targeted hepatitis vaccination programs should focus on adults who inject drugs to help prevent future infections.
Entities:
Keywords:
hepatitis A; hepatitis B; immunization information system; injection drug use; vaccination coverage
Authors: Jennifer V Campbell; Richard S Garfein; Hanne Thiede; Holly Hagan; Larry J Ouellet; Elizabeth T Golub; Sharon M Hudson; Danielle C Ompad; Cindy Weinbaum Journal: Drug Alcohol Depend Date: 2007-02-02 Impact factor: 4.492
Authors: Ruth Koepke; Ashley B Petit; Roman A Ayele; Jens C Eickhoff; Stephanie L Schauer; Matthew J Verdon; Daniel J Hopfensperger; James H Conway; Jeffrey P Davis Journal: J Public Health Manag Pract Date: 2015 May-Jun
Authors: Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward Journal: MMWR Recomm Rep Date: 2006-12-08
Authors: John Costumbrado; Ali Stirland; Garrett Cox; Alvin Nelson El-Amin; Armidia Miranda; Ann Carter; Mark Malek Journal: Vaccine Date: 2012-09-16 Impact factor: 3.641
Authors: Lauren J Stockman; Sheila M Guilfoye; Andrea L Benoit; James M Vergeront; Jeffrey P Davis Journal: MMWR Morb Mortal Wkly Rep Date: 2014-04-11 Impact factor: 17.586
Authors: Sarah Schillie; Claudia Vellozzi; Arthur Reingold; Aaron Harris; Penina Haber; John W Ward; Noele P Nelson Journal: MMWR Recomm Rep Date: 2018-01-12
Authors: Emmanuelle A Dankwa; Christl A Donnelly; Andrew F Brouwer; Rui Zhao; Martha P Montgomery; Mark K Weng; Natasha K Martin Journal: Vaccine Date: 2021-10-20 Impact factor: 4.169
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Paula M Frew; Jay T Schamel; Laura A Randall; Adrian R King; Ian W Holloway; Katherine Burris; Anne C Spaulding Journal: Int J Environ Res Public Health Date: 2021-02-04 Impact factor: 3.390